$1.5799
-0.0001[-0.01%]
Last update: 6:26PM Get Real Time Here
Inhibikase Therapeutics
(NASDAQ:IKT)Latest News for Inhibikase Therapeutics Stock (NASDAQ:IKT)
Inhibikase Therapeutics Stock (NASDAQ: IKT)
Categories: All
Monday, April 22, 2024
Thursday, April 18, 2024
Wednesday, April 03, 2024
Wednesday, March 27, 2024
Thursday, March 07, 2024
- HC Wainwright & Co. Reiterates Buy on Inhibikase Therapeutics, Maintains $27 Price TargetBenzinga Newsdesk - Mar 7, 2024, 11:26AM
- Inhibikase Therapeutics To Provide Trial Update For Risvodetinib At The 2024 International Conference On Alzheimer's and Parkinson's Diseases And Related Neurological DisordersBenzinga Newsdesk - Mar 7, 2024, 8:37AM
Tuesday, March 05, 2024
Wednesday, February 28, 2024
Monday, January 29, 2024
Friday, January 26, 2024
Thursday, January 25, 2024
Wednesday, January 24, 2024
Tuesday, January 16, 2024
Friday, January 05, 2024
Tuesday, December 19, 2023
Wednesday, December 13, 2023
Tuesday, December 12, 2023
Monday, December 11, 2023
Monday, December 04, 2023
Tuesday, November 14, 2023
- Inhibikase Therapeutics: Q3 Earnings InsightsBenzinga Insights - Nov 14, 2023, 4:40PM
- Inhibikase Therapeutics Q3 EPS $(0.86) Beats $(1.19) Estimate, Sales $79.57K Up From $7.29K YoYBenzinga Newsdesk - Nov 14, 2023, 4:36PM
- Earnings Scheduled For November 14, 2023Benzinga Insights - Nov 14, 2023, 8:23AM
Monday, November 13, 2023
Monday, October 16, 2023
Tuesday, October 10, 2023
Thursday, October 05, 2023
Wednesday, October 04, 2023
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga Insights - Oct 4, 2023, 1:31PM
- Why Cal-Maine Foods Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionLisa Levin - Oct 4, 2023, 12:48PM
- Market-Moving News for October 4thBenzinga Newsdesk - Oct 4, 2023, 8:43AM
- Inhibikase Therapeutics Receives FDA Orphan Drug Designation For Risvodetinib For Treatment Of Multiple System AtrophyBill Haddad - Oct 4, 2023, 8:30AM
Wednesday, September 20, 2023
- Reported Earlier, Inhibikase Therapeutics Issues A Letter To Shareholders And Comments On Recent Trading Activity; Says 'Unusually High Volume and Steep Declines in Price Have Impacted the Stock With No Identifiable CauseBenzinga Newsdesk - Sep 20, 2023, 11:45AM
- Why Fresh Tracks Therapeutics Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving PremarketLisa Levin - Sep 20, 2023, 8:19AM